BACK

Peter Garrambone, Jr.

Peter Garrambone, Jr.

Partner

New York Office  |  pete.garrambone@torreya.com   |   212.257.5808

Pete Garrambone is a Partner at Torreya and specializes in M&A and product/asset sales and licensing transactions. With over 35 years of experience as a business development professional in the healthcare industry, he has led and completed more than 50 transactions valued at over $250 billion.

Pete joined Torreya in 2008. Previously, he was a board member and interim CEO of Aegerion Pharmaceuticals, and Senior Vice President of Business Development at Reliant Pharmaceuticals.

Pete spent 24 years at Pfizer, where he served in several executive positions, including Senior Vice President of Corporate Strategic Planning and Business Development, Senior Vice President of the Medical Technology Group and Vice President Corporate Finance. While at Pfizer, Pete led numerous acquisition and divestiture transactions.

Notable transaction work prior to joining Torreya includes the sale of Reliant Pharmaceuticals to GlaxoSmithKline for $1.65 billion; Pfizer’s $117 billion acquisition of Warner-Lambert, $56 billion acquisition of Pharmacia, $1.3 billion acquisition of Esperion, and $1.9 billion acquisition of Vicuron; the divestiture of Pfizer’s consumer healthcare business to J&J for $16.6 billion; Pfizer’s divestiture of Schneider to Boston Scientific for $2.1 billion; and Pfizer’s divestiture of Howmedica to Stryker for $1.65 billion.

Pete graduated from Colby College with a B.A. in mathematics and economics, and holds an M.B.A. from The Tuck School of Business at Dartmouth.

Selected Transactions

Chiasma
Sale to
Amryt
$260 million
August 2021
Zylera
Sale to
Cerecor
Up to $34 million
November 2017
Mallinckrodt Pharmaceuticals
Sale of
Intrathecal business to
Piramal
$203 million
March 2017
Chelsea Therapeutics
Sale to
Lundbeck
$658 million
June 2014
Fibrotech
Sale to
Shire
$75 million upfront + milestones
May 2014
Flamel Technologies
Sale of Pessac plant to
Recipharm AB
Up to €22 million
November 2014
Zila
Sale of substantially
all assets to
DenMat
February 2014
Shionogi
Sale of Naprelan® to
Alvogen
November 2013
Shionogi
Divestiture of three pediatric drugs to
Concordia Pharmaceuticals
$28.7 million
May 2013
Clinigen
Acquisition of EU rights
to Vibativ® from
Theravance
$5 million + royalties
March 2013
Shionogi
Divestiture of
Cuvposa® to
Merz
August 2012
GTCR
Advisor in the acquisition of six products from
UCB
July 2010
DNP
Acquisition of
Thorne Research
$40 million +
milestones
June 2010